Brought to you by 
Lumena closes $45mm Series B round
27 Oct 2015
Executive Summary
Lumena Pharmaceuticals Inc. (treatments for rare liver and metabolic diseases) raised $45mm through its Series B round. First-time buyer New Enterprise Associates led, and was joined by other new investors Adage Capital Management and RA Capital Management, along with returning backers Pappas Ventures, RiverVest Venture Partners, and Alta Partners. Proceeds will fund trials of Lumena's apical sodium-dependent bile acid transporter inhibitors LUM001 (Phase II for cholestatic liver diseases) and LUM002 (entering Phase II for NASH, a silent liver disease that causes inflammation and fibrosis).
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Lumena closes $45mm Series B round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice